Skip to content
Peptide research

Hexarelin

Also known as Examorelin
Category
Growth Hormone
Administration routes
Injectable
Regulatory status
Not FDA-approved

A synthetic growth hormone secretagogue, the most potent of its class, used for muscle growth, recovery, and a claimed heart-protective effect. It reliably triggers a growth hormone surge in humans, but the heart, anti-fibrotic, and lipid benefits rest mainly on animal and mechanism-only studies. A known drawback is fast tolerance, plus prolactin and cortisol effects. It is not FDA-approved and is sold mostly as unregulated research product.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Hexarelin (also known by its pharmaceutical name examorelin) is a synthetic 6-amino-acid peptide and one of the most potent growth hormone-releasing peptides ever developed. Derived from GHRP-6, it works by activating the ghrelin receptor to trigger a substantial, dose-dependent increase in growth hormone levels — more than what the body's own growth hormone-releasing hormone (GHRH) can achieve alone. Beyond its growth hormone effects, hexarelin has shown significant heart-protective properties that work independently of growth hormone. It reached Phase II clinical trials for growth hormone deficiency and congestive heart failure but was never approved or brought to market.

How it works in the body

The most potent synthetic growth hormone secretagogue. It binds to ghrelin receptors (GHS-R1a) on pituitary cells with high affinity, producing a large, rapid burst of growth hormone. It also has direct cardioprotective effects through CD36 receptors on heart cells, independent of GH release.

Research overview

Hexarelin has been studied extensively in both laboratory and clinical settings since the 1990s. Its most notable finding is that it protects the heart through a mechanism completely separate from growth hormone — acting through the CD36 receptor on heart tissue to reduce scarring, prevent cell death, and slow atherosclerosis in animal models. In human studies (7 to 24 participants per trial), hexarelin increased the heart's pumping efficiency by 7-10 percentage points within 15-30 minutes of IV administration. However, a key limitation is that the body develops partial tolerance with ongoing use, with the mean GH response falling about 45% over 16 weeks in one human study. It can be given by injection (IV or subcutaneous), nasal spray, or orally, with a half-life of about 55-71 minutes. Development was discontinued before late-stage trials.

Who researches Hexarelin?

Commonly researched by

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People researching cardiovascular health

    Studied for effects on heart function, blood pressure, or vascular health.

Important considerations for

  • Those with Active cancer

    High

    GH secretagogue — sustained GH/IGF-1 elevation promotes tumor growth.

  • Those with Cardiovascular disease (severe)

    Moderate

    Hexarelin has direct cardiac effects via CD36 receptors. Use caution with existing heart conditions.

  • Those with Diabetic retinopathy

    High

    GH/IGF-1 elevation can worsen proliferative retinopathy.

  • Those with Diabetes/insulin resistance

    Moderate

    GH elevation can impair glucose tolerance and worsen insulin resistance.

Safety & interactions

Do not use if

  • Active cancer

    High

    GH secretagogue — sustained GH/IGF-1 elevation promotes tumor growth.

  • Diabetic retinopathy

    High

    GH/IGF-1 elevation can worsen proliferative retinopathy.

  • Cardiovascular disease (severe)

    Moderate

    Hexarelin has direct cardiac effects via CD36 receptors. Use caution with existing heart conditions.

  • Diabetes/insulin resistance

    Moderate

    GH elevation can impair glucose tolerance and worsen insulin resistance.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(7)

Rated by level of concern

  • Unapproved compound

    High

    No FDA or EMA approval record; WADA Prohibited List section S2 (GH secretagogues / GHRPs)

  • Limited long-term human safety data

    High

    PMID 9589671 (16-week twice-daily SC, GH status and body composition); PMID 10341859 (same cohort, pituitary-adrenal axis and prolactin)

  • HPA axis stimulation

    Moderate

    PMID 8954038 (dose-response study, cortisol rise of about 40%); PMID 15177700 (sleep - GH/ACTH/cortisol/prolactin); PMID 10341859 (16 weeks - cortisol AUC fell, ACTH AUC and UFC unchanged)

  • Prolactin elevation

    Moderate

    PMID 8954038 (dose-response, PRL plateau ~180%); PMID 15177700 (sleep); PMID 10341859 (16 weeks, no change in PRL AUC)

  • Tolerance development

    Moderate

    PMID 9589671 (GH status during long-term hexarelin therapy); PMID 10990150 (Rahim & Shalet, 'Does desensitization to hexarelin occur?'); PMID 9186261 (GHRP class review - partial desensitization)

  • Potential IGF-1 elevation concerns

    Theoretical

    PMID 9589671 (no significant IGF-1 or IGFBP-3 change over 20 weeks); mechanistic extrapolation from the GH/IGF-1 axis; no hexarelin-specific oncologic data

  • Water retention and joint discomfort

    Theoretical

    Class effect from recombinant GH literature; hexarelin tolerability and body-composition data PMID 9589671, PMID 10341859, PMID 8954038

Interaction summary(8)

Rated by direction with this peptide

  • GHRH and GHRH analogs (sermorelin, tesamorelin, CJC-1295)

    SynergisticModerate

    Directly demonstrated in humans, not inferred. Hexarelin and GHRH act via separate pituitary receptors: giving hexarelin with GHRH raised the GH AUC to 7395 vs 4693 for hexarelin alone, and even a low hexarelin dose with GHRH produced a large GH release. Co-administration amplifies GH exposure well beyond either agent alone. The specific analogs listed were not themselves tested with hexarelin; the extrapolation is from shared GHRH-receptor pharmacology.

    PMID 7731498 (hexarelin + GHRH in man); PMID 8954038 (low-dose hexarelin synergistic with GHRH-1-29)

  • Somatostatin analogs (octreotide, lanreotide, pasireotide)

    CautionLow

    Reduces efficacy rather than causing harm. IV somatostatin infusion (2 mcg/kg/h) blunted the GH response to hexarelin (AUC 4693 to 1314) while abolishing the response to GHRH - so hexarelin is partially resistant to somatostatin, not fully suppressed by it. The named long-acting analogs have not been tested with hexarelin; the expectation that they would blunt its primary pharmacologic effect is extrapolated.

    PMID 7731498 (somatostatin infusion blunted, did not abolish, the GH response to hexarelin)

  • Systemic glucocorticoids (prednisone, dexamethasone) and endogenous cortisol excess

    CautionModerate

    Studied in humans: the GH response to hexarelin was compared in subjects with and without glucocorticoid excess against GHRH, and glucocorticoid excess blunts (rather than abolishes) the GHRP response - notably, somatotrope responsiveness to GHRPs is near-absent in Cushing's syndrome. Hexarelin itself acutely raises ACTH and cortisol, so the two act on the same axis in a way that confounds both efficacy and any HPA-axis assessment.

    PMID 7561633 (GHRH vs hexarelin in humans with or without glucocorticoid excess); PMID 9186261 (GHRP class review - blunting by glucocorticoids, near-absent response in Cushing's); PMID 8954038

  • Other GHS-R1a agonists (ghrelin, GHRP-6, GHRP-2, ipamorelin, MK-677/ibutamoren)

    CautionModerate

    Shared-receptor pharmacology: using two agonists at the same receptor adds little incremental GH release while compounding receptor desensitization and the prolactin/ACTH/cortisol profile. Partial, reversible GH-axis attenuation is documented for hexarelin itself over 16 weeks. No study has formally tested hexarelin with another GHS-R1a agonist, so the magnitude of the combined effect is inferred from class pharmacology.

    Shared GHS-R1a pharmacology; hexarelin desensitization PMID 9589671, PMID 10990150; class review PMID 9186261

  • Exogenous growth hormone (somatropin) or IGF-1 (mecasermin)

    CautionLow

    Two opposing effects, neither studied for this combination. Pharmacodynamically, recombinant human GH blunts rather than adds to the GHRP-induced GH response via negative feedback. Pharmacologically, additive GH/IGF-1 exposure would be expected to raise the likelihood of fluid retention, arthralgia, insulin resistance, and supraphysiologic IGF-1. Entirely mechanism-based - no hexarelin-plus-somatropin or hexarelin-plus-mecasermin data exist.

    Mechanism-based; GHRP feedback blunting by rhGH described in class review PMID 9186261; somatropin class safety from product labeling

  • Insulin and other glucose-lowering agents (metformin, sulfonylureas, GLP-1 agonists)

    CautionTheoretical

    GH is counter-regulatory to insulin, so a sustained GH secretagogue effect could in principle reduce insulin sensitivity and shift glycemic control, warranting monitoring. This has never been studied for hexarelin - no published hexarelin trial reported glucose or insulin outcomes, and the 16-week study found no change in body composition, so the premise is untested at studied doses.

    Mechanism-based extrapolation from GH physiology; no hexarelin-specific glycemic data identified

  • Dopamine agonists (cabergoline, bromocriptine)

    ProtectiveTheoretical

    Purely mechanistic. Dopaminergic suppression of pituitary lactotrophs would be expected to offset hexarelin's acute prolactin rise (which plateaus around a 180% increase from baseline with IV dosing). No study has tested this combination, and no clinical hyperprolactinemia has been reported with hexarelin, so the 'protective' framing describes a plausible mechanism, not a demonstrated benefit or a clinical need.

    Mechanism-based; hexarelin prolactin dose-response PMID 8954038

  • Thiazolidinediones and other PPAR-gamma agonists (pioglitazone)

    SynergisticTheoretical

    Preclinical convergence only, and the evidence argues against simple additivity. Hexarelin's CD36-mediated effect involves PPAR-gamma transcriptional activation, but chromatin immunoprecipitation showed hexarelin and a classical PPAR-gamma agonist drive different target-gene occupancy (hexarelin favored LXR-alpha, not CD36). No study has combined hexarelin with a thiazolidinedione in any species, and there is no human relevance. Included for completeness; carries no practical clinical implication.

    PMID 16959872 (differential PPARgamma target-gene regulation by hexarelin vs PPARgamma agonist); PMID 18288286; PMID 29883404

Known risks(7)

  • HPA axis stimulation

    Hexarelin significantly increases cortisol and ACTH levels via stimulation of arginine vasopressin (AVP) release. Chronic HPA axis activation may lead to adrenal-related side effects.

  • Prolactin elevation

    Hexarelin slightly but consistently stimulates prolactin release, which could cause hyperprolactinemia-related effects (gynecomastia, galactorrhea, reduced libido) with chronic use.

  • Tolerance development

    A partial and reversible tolerance develops with long-term administration, with the mean GH response falling about 45% over 16 weeks in one human study, significantly limiting chronic therapeutic use.

  • Limited long-term human safety data

    Hexarelin never completed Phase III trials, so comprehensive long-term safety, carcinogenicity, reproductive toxicity, and chronic use data are unavailable.

  • Potential IGF-1 elevation concerns

    While reports are conflicting, hexarelin may increase IGF-1 levels, which is associated with theoretical cancer risk with sustained elevation.

  • Water retention and joint discomfort

    As with other GH secretagogues, potential for GH-related side effects including water retention, joint pain, and carpal tunnel-like symptoms, particularly at higher doses.

  • Unapproved compound

    Hexarelin is not manufactured under pharmaceutical GMP standards when bought as unregulated products sold online, posing risks of impurity, incorrect dosing, and contamination.

Drug interactions(6)

  • GHRH (Growth Hormone-Releasing Hormone)

    Synergistic — combination produces massive GH release even at low doses of hexarelin. Clinically documented synergy.

  • Somatostatin and analogs (octreotide, lanreotide)

    Antagonistic — somatostatin inhibits GH release and may attenuate hexarelin's GH-releasing effects, though hexarelin partially overcomes somatostatin suppression.

  • Exogenous growth hormone (rhGH)

    Potential additive effects on IGF-1 elevation. Concurrent use may increase risk of GH-related side effects. No direct pharmacokinetic interaction documented.

  • Glucocorticoids

    Hexarelin stimulates cortisol release via AVP; concurrent glucocorticoid use may compound HPA axis effects and cortisol-related side effects.

  • Insulin and insulin secretagogues

    GH elevation by hexarelin induces insulin resistance. May require dose adjustments in diabetic patients on insulin or oral hypoglycemics.

  • Other GH secretagogues (GHRP-2, GHRP-6, ipamorelin, MK-677)

    Additive GH release when combined. Increased risk of tolerance development, prolactin elevation, and cortisol stimulation.

Research & benefits

Evidence base

Evidence Level
Phase II — Moderate
Total Studies
25
Human Studies
6

Hexarelin reached Phase II clinical trials for GH deficiency and congestive heart failure. Human studies (total ~50 subjects across multiple trials) demonstrate consistent GH release and acute cardioprotective effects. However, development was discontinued before Phase III, tolerance development limits chronic use, and the compound was never marketed. Preclinical evidence for cardioprotection is robust, but translational human data remains limited.

Researched for(6)

Rated by confidence in the evidence

  • Potent growth hormone release

    High

    Multiple human studies confirm dose-dependent growth hormone release, exceeding GHRH in direct comparison.

    PMID 8954038 (dose-response GH/cortisol/prolactin, healthy adult males); PMID 7731498 (GH-releasing activity and its modulation in man); PMID 7561633 (vs GHRH in humans); PMID 9437229 (age-related variation)

  • Cardioprotection and improved cardiac function

    Medium

    Small human studies, including controlled comparisons, show acute cardiac function improvement in some but not all conditions.

    PMID 10528131 (cardiac effects in hypopituitary adults); PMID 11959048 (GH-independent cardiotropic activity, iCMP vs dCMP); PMID 10342360 (acute cardiovascular and hormonal effects of GH and hexarelin in humans); PMID 12144941 (acute hexarelin during bypass surgery)

  • Anti-fibrotic cardiac effects

    Low

    Reduced cardiac fibrosis in rodent and cell studies only; no human data available.

    PMID 17766487 (rat cardiac fibroblasts, GHSR + adenosine A2R); PMID 22842067 (chronic hexarelin attenuates cardiac fibrosis in the SHR, Am J Physiol Heart Circ Physiol 2012, doi:10.1152/ajpheart.00257.2011); PMID 29756411 (mouse acute MI); PMID 24747279 (oral hexarelin after MI)

  • Ischemia-reperfusion injury protection

    Low

    Animal study only; suggests ischemia-reperfusion protection, but mechanism largely unconfirmed in humans.

    PMID 28321024 (rat in vivo I/R, IL-1 signaling)

  • Anti-atherosclerotic activity

    Low

    Reduced atherosclerotic plaque in mouse studies via a well-characterized mechanism; no human data.

    PMID 16959872 (Avallone 2006, Mol Endocrinol - hexarelin, CD36/GHS-R1a, PPARgamma, apoE-null mice); PMID 16123174 (Marleau 2005, FASEB J - EP80317 in apoE-null mice); PMID 18288286 (Demers et al., PPAR Res 2008;2008:364784, PMC2233980); PMID 29883404 (CD36-PPARgamma review, PMC5983591)

  • Lipid metabolism improvement

    Speculative

    Mechanism-based only; no human trial has reported changes to cholesterol or triglycerides.

    PMID 16959872; PMID 18288286 (Demers et al., PPAR Res 2008;2008:364784); PMID 29883404 (CD36-PPARgamma review); PMID 9589671 (16-week human study - no change in body composition)

Benefits(6)

  • Potent growth hormone release

    Phase II trials showed dose-dependent GH increases exceeding GHRH alone; synergistic effects with GHRH produce massive GH elevation even at low doses (Bisi et al., 1999; Ghigo et al., multiple studies)

  • Cardioprotection and improved cardiac function

    Increased LVEF from 64% to 70.7% in healthy volunteers (n=7, p<0.03) and improved cardiac performance in bypass surgery patients (n=24, p<0.001) via GH-independent CD36 receptor activation (Bisi et al., 1999; Broglio et al., 2002)

  • Anti-fibrotic cardiac effects

    In mouse MI model, 21-day hexarelin treatment (0.3 mg/kg/day SC) reduced interstitial collagen staining from 7.62% to 2.15% (about 72% lower) and improved EF from 37% to 49% (McDonald et al., 2018)

  • Ischemia-reperfusion injury protection

    Reduced infarct size by 25-40% in rat models; cardioprotection mediated via CD36 receptor (abolished in CD36 knockout, preserved in GHS-R1a knockout mice) (Mao et al., 2014 review)

  • Anti-atherosclerotic activity

    In rat atherosclerosis model (200 mcg/kg/day x 30 days), suppressed plaque formation, reversed cholesterol ratios, and increased nitric oxide levels (Mao et al., 2014)

  • Lipid metabolism improvement

    Improved lipid metabolic aberrations in non-obese insulin-resistant MKR mouse model (Mosa et al., 2017, PMC5659698)

Key studies(6)

  1. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans

    Randomized controlled trial7 healthy male volunteersSingle-dose acute study (90 min observation)

    Bisi G, Podio V, Valetto MR, Broglio F, Bertuccio G, Del Rio G, Arvat E, Boghen MF, Deghenghi R, Muccioli G, Ong H, Ghigo E

    Journal of Endocrinology and Investigation

    1999

    Hexarelin (2 mcg/kg IV) increased LVEF from 64.0% to 70.7% (p<0.03), peaking at 30 min and lasting 60 min, with no change in BP or HR. Effect was GH-independent, suggesting specific myocardial GHS receptors.

  2. Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery

    Randomized controlled trial24 male patients with CADSingle-dose acute study (90 min observation during bypass surgery)

    Broglio F, Guarracino F, Benso A, Gottero C, Prodam F, Granata R, Avogadri E, Muccioli G, Deghenghi R, Ghigo E

    European Journal of Pharmacology

    2002

    Hexarelin (2 mcg/kg IV) significantly improved LVEF (p<0.001), cardiac index (p<0.001), and cardiac output (p<0.001) within 10 min, sustained for 90 min. Wedge pressure decreased (p<0.01). Effects were GH-independent.

  3. Cardiac effects of hexarelin in hypopituitary adults

    Clinical trial7 GH-deficient patients + 9 controlsSingle-dose acute study

    Bisi G, Podio V, Valetto MR, Broglio F, Bertuccio G, Aimaretti G, Pelosi E, Del Rio G, Muccioli G, Ong H, Boghen MF, Deghenghi R, Ghigo E

    European Journal of Pharmacology

    1999

    Hexarelin increased LVEF in both GH-deficient patients (50% to 57%, p<0.05) and controls (63% to 70%, p<0.05) without changing catecholamine levels, BP, or cardiac output. Confirmed GH-independent positive inotropic effect.

  4. The cardiovascular action of hexarelin

    Comprehensive reviewN/A (review of multiple studies)

    Mao Y, Tokudome T, Kishimoto I

    Journal of Geriatric Cardiology

    2014

    Comprehensive review establishing hexarelin's cardioprotective effects through dual GHS-R1a and CD36 receptor pathways. Documented anti-fibrotic, anti-apoptotic, anti-atherosclerotic, and positive inotropic effects independent of GH release.

  5. McDonald H, Peart J, Kurniawan N, Galloway G, Royce S, Samuel CS, Chen C

    Physiological Reports

    2018

    Hexarelin (0.3 mg/kg/day SC) improved EF from 37% to 49% (p<0.05) at 14 days, reduced interstitial collagen staining by about 72% (7.62% to 2.15%), decreased inflammatory cytokines (TNF-alpha, IL-1beta), and increased MMP-13 expression sixfold.

  6. Korbonits M, Kaltsas G, Perry LA, Putignano P, Grossman AB, Besser GM, Trainer PJ

    Journal of Clinical Endocrinology & Metabolism

    1999

    Hexarelin stimulates the HPA axis via arginine vasopressin (AVP) release rather than CRH, explaining the cortisol and ACTH elevations observed with GHS administration.

What research suggests over time

  • Hours-Days

    Phase II RCT

    Acute GH release peaks 30-60 min after IV injection; LVEF improvement noted within 30 min of a single dose in cardiac trials.

  • Weeks 2-4

    Phase II

    In one 16-week human study, repeated treatment reduced the GH response without significantly changing IGF-1 levels or body composition.

  • Long-term

    Phase II

    Phase II reached for GH deficiency and congestive heart failure; LVEF rose from 64% to 70% in healthy controls and 50% to 57% in GH-deficient patients (J Endocrinol 1999).

Regulation & availability

Why researchers look at it

One of the most potent GH secretagogues ever developed, but the more compelling finding is its heart-protective activity — working through receptor CD36, entirely independent of growth hormone, it improved cardiac pumping efficiency by 7-10 percentage points within minutes in human studies. Development stalled because the body builds tolerance to its GH effects within weeks, and it reached only Phase II before discontinuation. If a tolerance-resistant analog were developed, it could reopen a uniquely promising line of cardiovascular research.

Estimated cost
No approved product and no verified reference price
FDA status
Not FDA-approved. Hexarelin (examorelin) is an investigational new drug that reached Phase II clinical trials for growth hormone deficiency and congestive heart failure but was discontinued before Phase III. It has no IND currently active with the FDA, no NDA has been filed, and it has no assigned ATC code. The FDA's 2023-2024 tightening of regulations on peptide compounding has further restricted its availability through compounding pharmacies.
WADA status
PROHIBITED — Hexarelin is banned by the World Anti-Doping Agency (WADA) under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics, specifically as a Growth Hormone-Releasing Peptide (GHRP). It is prohibited both in-competition and out-of-competition. This prohibition is confirmed on the 2026 Prohibited List, which came into force on January 1, 2026 (approved by WADA Executive Committee on September 11, 2025). Athletes found using hexarelin face sanctions including multi-year bans.
Prescribability
No — Hexarelin is an investigational compound that never completed clinical development and was never approved by the FDA or any other regulatory agency. It is not available as a prescription medication.
Availability
Hexarelin is NOT approved for clinical use in any country. It never completed clinical development and was never marketed as a pharmaceutical product. It is classified as a WADA prohibited substance (S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics — GH-Releasing Peptides). It is not scheduled as a controlled substance in most jurisdictions but is regulated as an unapproved drug. Compounding pharmacies in the United States do not typically compound hexarelin due to its unapproved status and FDA restrictions on peptide compounding that tightened in 2023-2024.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(10)

  1. Early 1990s
    Hexarelin (examorelin) synthesized as a derivative of GHRP-6 by Mediolanum Farmaceutici
  2. 1990s
    Phase I clinical trials conducted — established safety and GH-releasing efficacy in healthy volunteers
  3. 1999
    Multiple Phase II clinical studies published — cardiovascular effects demonstrated in healthy subjects (Bisi et al.), hypopituitary patients (Bisi et al.), establishing GH-independent cardiac effects
  4. 2002
    Phase II cardiac study in bypass surgery patients (Broglio et al., n=24) — demonstrated significant improvement in cardiac performance
  5. ~2003-2005
    Clinical development discontinued — tolerance development and lack of clear advantage over emerging alternatives led to termination before Phase III
  6. 2004+
    Listed on WADA Prohibited List as a growth hormone-releasing peptide (S2 category)
  7. 2014
    Major review of cardiovascular actions published (Mao et al., J Geriatr Cardiol) — consolidated evidence for CD36-mediated cardioprotection
  8. 2018
    McDonald et al. publish mouse MI study showing preserved myocardial function and reduced fibrosis with hexarelin treatment
  9. 2023-2024
    FDA tightens regulations on peptide compounding, further restricting hexarelin availability through compounding pharmacies in the US
  10. January 1, 2026
    Hexarelin remains on WADA 2026 Prohibited List (S2 category), confirmed prohibited in- and out-of-competition

Sources & FAQs

Research sources(9)

Frequently asked questions(6)

What is hexarelin and how does it work?

Hexarelin (examorelin) is a synthetic hexapeptide that stimulates growth hormone release by binding to the GHS-R1a (ghrelin receptor) in the pituitary and hypothalamus. It also binds to CD36 receptors on heart tissue, providing cardioprotective effects independent of GH release. Its amino acid sequence is His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2.

How does hexarelin compare to other GH secretagogues like GHRP-6 or ipamorelin?

Hexarelin is considered the most potent GHRP for GH release but also has the strongest cortisol and prolactin stimulation. Unlike ipamorelin (which is selective for GH only), hexarelin activates the HPA axis via AVP release. A distinguishing feature is CD36-mediated cardioprotection not shared by other GHRPs. However, it develops tolerance (about a 45% reduction over 16 weeks in one human study) faster than some other GHRPs.

Does hexarelin cause tolerance?

Yes. A partial tolerance to hexarelin's GH-releasing effects develops with long-term use, with the mean GH response falling about 45% over 16 weeks in one human study. The tolerance appears to be reversible after discontinuation. This was a significant factor in its clinical development challenges.

Is hexarelin safe for human use?

Hexarelin has been given intravenously to humans in Phase II clinical trials without serious adverse events reported. However, it was never approved and lacks the comprehensive safety data from Phase III trials. Known hormonal effects include increases in cortisol, ACTH, and prolactin. Long-term safety in humans has not been established.

Can hexarelin be used in sports?

No. Hexarelin is explicitly prohibited by the World Anti-Doping Agency (WADA) under section S2 of the Prohibited List as a growth hormone-releasing peptide. It is banned both in-competition and out-of-competition. Testing methods exist to detect hexarelin and its metabolites.

What are hexarelin's cardiac benefits?

Clinical studies show hexarelin acutely increases left ventricular ejection fraction by 7-10 percentage points in both healthy individuals and cardiac patients. Animal studies demonstrate it reduces cardiac fibrosis by ~53%, decreases infarct size by 25-40% in ischemia-reperfusion models, has anti-atherosclerotic properties, and protects against cardiomyocyte apoptosis. These effects are mediated through CD36 receptors, independent of GH release.